Virtual Library

Start Your Search

Fumie Shigematsu



Author of

  • +

    EP1.04 - Immuno-oncology (ID 194)

    • Event: WCLC 2019
    • Type: E-Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
    • +

      EP1.04-33 - Pembrolizumab with High PD-L1: Who Are Non-Responders? (Now Available) (ID 3003)

      08:00 - 18:00  |  Presenting Author(s): Fumie Shigematsu

      • Abstract
      • Slides

      Background

      Pembrolizumab is a programmed death-1 (PD-1) blockade which is approved for non-small cell lung cancer (NSCLC). It has been reported that programmed death-ligand 1 (PD-L1) high patients are more effective than low patients to pembrolizumab. It has not been clear what factors decide responsiveness to pembrolizumab in PD-L1 high patients.

      Method

      NSCLC patients who had been given pembrolizumab from April 2017 to October 2018 in Nagoya Medical Center and whose PD-L1 tumor proportion score (TPS) was ≥50% were included. A double cancer case was excluded. The non-effective group was made of patients who had stable and progressive diseases, and the effective group was made of patients who had complete and partial response. We compared the non-effective group with the effective group.

      Result

      Data were extracted retrospectively from patients' medical records. In total, 34 patients received pembrolizumab. One patient who had double cancer and 7 patients whose PD-L1 TPS was <50% were excluded from this analysis. Twenty-six patients were included. In 26 patients, 19 men (73.1%), 22 current or former smokers (84.6%). The median age was 69 (ranged 48–88). Patients with adenocarcinoma, adenosquamous, squamous, not otherwise specified, and pleomorphic carcinoma were 15/1/ 8/1/1. Stage IIIA, IIIB, IV, and recurrence after surgery were 1/2/16/ 7. Performance status (PS) 0, 1, 2, 3, and 4 were 7/9/7/ 2/1. First, second, and fourth lines of chemotherapy were 18, 7, and 1, respectively. Differences between pembrolizumab effective and non-effective group in gender, smoking history, age, tissue type, proportion of stage IV, and treatment line were not statistically different. In terms of PS, all PS 3 or 4 patients were non-effective.

      Conclusion

      In NSCLC PD-L1 high patients treated with pembrolizumab, PS 3–4 might be a factor, which indicated poor response to pembrolizumab.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.